C/EBPβ Cooperates with MYB to Maintain Oncogenic Program of AML Cells | Oncotarget

Posted by

Oncotarget

Oncotarget published this editorial perspective on March 11, 2023 in Volume 14, entitled, “C/EBPβ cooperates with MYB to maintain the oncogenic program of AML cells” by Karl-Heinz Klempnauer from the Institute for Biochemistry, Westfälische-Wilhelms-Universität, Muenster D-48149, Germany. DOI - https://doi.org/10.18632/oncotarget.28377 Correspondence to - Karl-Heinz Klempnauer - klempna@uni-muenster.de Abstract Studies on the role of transcription factor MYB in acute myeloid leukemia (AML) have identified MYB as a key regulator of a transcriptional program for self-renewal of AML cells. Recent work summarized here has now highlighted the CCAAT-box/ enhancer binding protein beta (C/EBPβ) as an essential factor and potential therapeutic target that cooperates with MYB and coactivator p300 in the maintenance of the leukemic cells. Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28377 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, MYB, C/EBPbeta, p300, GFI1, AML About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957